Key facts
- Notable investors include National Institutes of Health.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Zegenex
- ·The full record, as it builds
Funding rounds
No funding rounds for Zegenex are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Zegenex
Developer of a medicated wound healing product designed to facilitate tissue repair and reduce scar formation during the recovery process. The company offers patented, biologically inspired formulations that activate natural healing mechanisms, enabling healthcare providers to promote consistent healing and improved recovery for patients with acute and chronic wounds.
- Sector
- Healthcare
- HQ
- Pittsburgh, PA, United States
- Founded
- 2023
- Employees
- 1
- Website
- zegenex.com/
- Ownership
- Privately Held (backing)
Zegenex doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Zegenex shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Zegenex in its N-PORT filings yet. We sweep new filings monthly.